三月 2026
- Home
- Ariad Pharmaceuticals Inc
三月 2026的Ariad Pharmaceuticals Inc市场份额分析
our mission is to discover, develop and commercialize small-molecule medicines to treat cancer in patients with the greatest unmet medical need—those with aggressive cancers where current therapies are inadequate. we are committed to the highest standards of integrity and stewardship in service to patients, the medical community, employees and shareholders.
Ariad Pharmaceuticals Inc(包含公司地区分支机构)
查看更多网站流量和参与度信息- ariad.com
Ariad Pharmaceuticals Inc收入截至 三月 2026为 100M - 200M
Ariad Pharmaceuticals Inc主要域名产生的收入
3 年中Ariad Pharmaceuticals Inc主要域名的收入
Ariad Pharmaceuticals Inc主要域名的收入
Ariad Pharmaceuticals Inc热门域名的总访问量
了解Ariad Pharmaceuticals Inc市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Ariad Pharmaceuticals Inc热门域名的平均访问时长
分析Ariad Pharmaceuticals Inc参与度指标。
过去 3 个月的平均访问时长
无数据可显示
无数据可显示
Ariad Pharmaceuticals Inc热门域名的平均页面浏览量
了解Ariad Pharmaceuticals Inc如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Ariad Pharmaceuticals Inc 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Knickerbocker leaves Ariad as Vice President, Biomedical Data Sciences and Information.Dr. Knickerbocker joins BioCanCell from ARIAD Pharmaceuticals, where he was Vice President, Biomedical Data Sciences and Information and led the Biostatistics and Data Management functions through multiple successful oncology submissions.
三月 6, 2018阅读更多
新闻Sergio Santillana leaves Ariad as CMO.The new CMO, Sergio Santillana comes from Ariad , and Ellen Forest, head of human resources, previously served at Baxalta .
六月 9, 2017阅读更多
新闻Takeda Pharmaceuticals acquired Ariad for $5.2B on Feb 16th '17.Takeda took a chance a few weeks ago when it acquired Ariad with lead pipeline prospect Alunbrig still under regulatory review in the US.
四月 28, 2017阅读更多
查看 Ariad Pharmaceuticals Inc 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。